2型糖尿病治疗新药坎格列净的研究进展  

Research Progress in New Drug Canagliflozin for the Treatment of Type 2 Diabetes

作　　者：安富荣[1] 崔岚[1] 王勤[1] 

机构地区：[1]上海交通大学医学院附属仁济医院药剂科,上海200001

出　　处：《中国药师》2014年第7期1211-1214,共4页China Pharmacist

摘　　要：坎格列净是一种钠-葡萄糖共转运蛋白2抑制药,抑制葡萄糖的肾重吸收,增加葡萄糖的尿排泄。美国FDA于2013年3月批准其上市,用于治疗2型糖尿病。坎格列净可有效降低2型糖尿病患者的血糖水平,还可降低患者体质量和收缩压,且低血糖风险较小。不良反应是增加泌尿生殖道感染。本文就其作用机制、药动学、临床疗效及安全性等作一综述。Canagliflozin is a sodium-glucose co-transport protein 2 （SGLT2） inhibitor for the treatment of type 2 diabetes.It can inhibit renal reabsorption of glucose,thereby increase urinary glucose excretion.It obtained market approval in March,2013 certified by FDA and was applied in the treatment of type 2 diabetes.Canagliflozin is effective in reducing glycaemic levels in patients with type 2 diabetes.It can reduce the body weight and systolic blood pressure of patients with low risk of hypoglycemia.The adverse effects include increased risk of urinary tract infections and genital mycotic infections.The pharmacological mechanism,pharmacokinetics,clinical efficacy and safety of canagliflozin were summarized in this paper.

关 键 词：坎格列净 2型糖尿病 钠-葡萄糖共转运蛋白2抑制药 临床研究 

分 类 号：R977.15[医药卫生—药品]